申请人:Davidson Alan Hornsby
公开号:US20090131461A1
公开(公告)日:2009-05-21
Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y
1
, L
1
and z are as defined in the claims; R
6
is C
1
-C
4
alkoxy, hydrogen or halo; W represents a bond, —CH
2
—, —O—, —S—, —S(═O)
2
—, or NR
5
— where R
5
is hydrogen or C
1
-C
4
alkyl; Q is ═N—, ═CH— or ═C(X
1
)— wherein X is cyano, cyclopropyl or halo; linker radicals L are as defined in the claims; R is a radical of formula (X) or (Y): wherein R
1
is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R
4
is hydrogen; or optionally substituted C
1
-C
6
alkyl, C
3
-C
7
cycloalkyl, aryl, aryl(C
1
-C
6
alkyl)-, heteroaryl, heteroaryl(C
1
-C
6
alkyl)-, —(C═O)R
3
, —(C═O)OR
3
, or —(C═O)NR
3
wherein R
3
is hydrogen or optionally substituted (C
1
-C
6
)alkyl, C
3
-C
7
cycloalkyl, aryl, aryl(C
1
-C
6
alkyl)-, heteroaryl, or heteroaryl(C
1
-C
6
alkyl)-; R
4
1
is hydrogen or optionally substituted C
1
-C
6
alkyl; and D is a mono-cyclic heterocyclic ring of 5 or 6 ring atoms.
公式(IA)或(IB)的化合物是aurora激酶活性的抑制剂:公式(IA),(IB)其中-L1Y1-[CH2]z-是一个连接基团,其中Y1,L1和z如权利要求中所定义;R6是C1-C4烷氧基,氢或卤素;W代表键,—CH2—,—O—,—S—,—S(═O)2—或NR5—,其中R5是氢或C1-C4烷基;Q是═N—,═CH—或═C(X1)—,其中X是氰基,环丙基或卤素;连接基团L如权利要求中所定义;R是公式(X)或(Y)的基团:其中R1是羧酸基(—COOH),或可由一个或多个细胞内羧酸酯酶水解为羧酸基的酯基团;R4是氢;或者是可选的取代C1-C6烷基,C3-C7环烷基,芳基,芳基(C1-C6烷基)-,杂环芳基,杂环芳基(C1-C6烷基)-,—(C═O)R3,—(C═O)OR3或—(C═O)NR3,其中R3是氢或可选的取代(C1-C6)烷基,C3-C7环烷基,芳基,芳基(C1-C6烷基)-,杂环芳基或杂环芳基(C1-C6烷基)-;R41是氢或可选的取代C1-C6烷基;D是一个由5或6个环原子组成的单环杂环。